MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Purpose: This study aimed to investigate the changes in microRNA-130a (miR-130a) and its correlation with cardiotoxicity during epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab (EC-D+T) adjuvant chemotherapy in human epidermal growth factor receptor-2-positive (HER2+ ) breast cancer patients.
Methods: A total of 72 HER2+ breast cancer patients who underwent resection and were scheduled to receive EC-D+T adjuvant therapy were consecutively enrolled. The expression of miR-130a and cardiotoxicity (defined as any of the following situations: 1) absolute decline of left ventricular ejection fraction (LVEF) ≥ 10% and LVEF < 53%; 2) heart failure; 3) acute coronary artery syndromes; and 4) fatal arrhythmia) were assessed every 3 months throughout the 15-month EC-D+T treatment.
Results: The accumulating cardiotoxicity rate was 12 (16.7%), of which the incidence of heart failure, acute coronary syndrome, life-threatening arrhythmias, ΔLVEF ≥ 10%, and LVEF < 53% was 0 (0.0%), 1 (1.4%), 0 (0.0%), and 12 (16.7%), respectively. Baseline miR-130a expression was negatively correlated with LVEF (%) and positively correlated with cardiac troponin I. The expression of miR-130a gradually increased in both cardiotoxicity and noncardiotoxicity patients during EC-D+T treatment, while the increment of miR-130a was more obvious in cardiotoxicity patients compared with non-cardiotoxicity patients. Further logistic regression and receiver operating characteristic curve analysis indicated that miR-130a was an independent predictive factor for increased cardiotoxicity risk.
Conclusion: MiR-130a increases constantly and predicts high cardiotoxicity risk during ECD+T adjuvant chemotherapy in HER2+ breast cancer patients.

번역하기

참고문헌 (Reference)

1 Yin Z, "miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway" 8 : 192-207, 2016

2 Slamon DJ, "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2" 344 : 783-792, 2001

3 Balduzzi S, "Trastuzumab-containing regimens for metastatic breast cancer" 2014 : CD006242-, 2014

4 Nemeth BT, "Trastuzumab cardiotoxicity : from clinical trials to experimental studies" 174 : 3727-3748, 2017

5 Kim GH, "Translational control of FOG-2 expression in cardiomyocytes by microRNA-130a" 4 : e6161-, 2009

6 Zhang HD, "The role of miR-130a in cancer" 24 : 521-527, 2017

7 Liu H, "Role of microRNA-130a in myocardial hypoxia/reoxygenation injury" 13 : 759-765, 2017

8 Lang RM, "Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology" 18 : 1440-1463, 2005

9 Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging" 28 : 1e14-39e14, 2015

10 Zhao L, "MicroRNA-140-5p aggravates doxorubicin-induced cardiotoxicity by promoting myocardial oxidative stress via targeting Nrf2 and Sirt2" 15 : 284-296, 2018